Reaction

Oesophageal Disorder reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 3,808 reports · 84 co-occurring drugs

As of the last recalculation, Oesophageal Disorder appears in 3,808 FAERS reports alongside 84 co-occurring drug terms. The strongest observed disproportionality signal is ESOMEPRAZOLE MAGNESIUM (PRR 11.9).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Esomeprazole Magnesium	455	11.9	12.0
Alendronate Sodium	165	9.3	9.3
Hyoscyamine Sulfate	15	9.0	9.0
Sucralfate	37	8.5	8.5
Risedronate Sodium	44	7.8	7.8
Quinine	12	7.7	7.7
Sucralfate Oral	19	7.3	7.3
Sucralfate Oral Suspension	19	7.3	7.3
Raloxifene Hydrochloride	19	7.1	7.2
Extended Phenytoin Sodium	20	6.6	6.6
Meperidine Hydrochloride	11	6.5	6.5
Indapamide	20	6.1	6.1
Diphenoxylate Hydrochloride And Atropine Sulfate	14	5.6	5.6
Carisoprodol	17	4.9	4.9
Tiotropium Bromide Inhalation Spray	10	4.9	4.9
Ipratropium Bromide	31	4.8	4.8
Zinc	21	4.7	4.7
Zinc Chloride	21	4.6	4.6
Rabeprazole Sodium	23	4.6	4.6
Butalbital, Acetaminophen, And Caffeine	9	4.6	4.6
Zinc Gluconate	21	4.4	4.4
Omeprazole Magnesium	333	4.4	4.4
Crizotinib	10	4.3	4.3
Insulin Glulisine	8	4.3	4.3
Oxycodone And Acetaminophen Tablets	9	4.1	4.1
Dexlansoprazole	30	4.0	4.0
Timolol Maleate	7	3.9	3.9
Teriparatide	76	3.7	3.7
Dofetilide	7	3.6	3.6
Mirabegron	25	3.5	3.6
Doxazosin	18	3.5	3.5
Carboxymethylcellulose Sodium	6	3.5	3.5
Ibuprofen Tablets, Coated	26	3.4	3.4
Ibuprofen Sodium	26	3.3	3.3
Nintedanib	19	3.3	3.3
Budesonide And Formoterol Fumarate Dihydrate	58	3.3	3.3
Tafamidis	7	3.3	3.3
Budesonide, Glycopyrrolate, And Formoterol Fumarate	6	3.1	3.1
Brivaracetam	5	3.0	3.0
Macitentan	38	3.0	3.0
Mepolizumab	27	3.0	3.0
Prochlorperazine Maleate	5	3.0	3.0
Acetaminophen, Aspirin (Nsaid) And Caffeine	9	2.9	2.9
Acetaminophen, Aspirin, And Caffeine	11	2.9	2.9
Loratadine And Pseudoephedrine Sulfate	4	2.8	2.8
Icosapent Ethyl	4	2.6	2.6
Calcium, Magnesium, Potassium, And Sodium Oxybates	4	2.5	2.5
Bimekizumab	9	2.3	2.3
Palbociclib	40	2.3	2.3
Treprostinil	52	2.3	2.3
Dabigatran Etexilate Mesylate	30	2.3	2.3
Fluticasone Propionate And Salmeterol	17	2.2	2.2
Niraparib	9	2.2	2.2
Dabigatran Etexilate	30	2.1	2.1
Vibegron	3	2.0	2.0
Buprenorphine Hydrochloride, Naloxone Hydrochloride	9	2.0	2.0
Eculizumab	20	2.0	2.0
Umeclidinium Bromide And Vilanterol Trifenatate	6	2.0	2.0
Naproxen Sodium Tablet	19	2.0	2.0
Belimumab	11	1.9	1.9
Isotretinoin	17	1.9	1.9
Enzalutamide	20	1.9	1.9
Rucaparib	3	1.9	1.9
Atezolizumab	13	1.8	1.8
Interferon Beta-1A	64	1.8	1.8
Hydrocodone Bitartrate	13	1.6	1.6
Elvitegravir, Cobicistat, Emtricitabine, And Tenofovir Alafenamide	3	1.6	1.6
Conjugated Estrogens And Medroxyprogesterone Acetate	7	1.6	1.6
Pirfenidone	12	1.6	1.6
Cabozantinib	13	1.5	1.5
Onabotulinumtoxina	20	1.4	1.4
Somatropin	19	1.4	1.4
Ambrisentan	30	1.3	1.3
Velpatasvir And Sofosbuvir	3	1.3	1.3
Ranitidine Hydrochloride	12	1.2	1.2
Patiromer	3	1.2	1.2
Icodextrin, Sodium Chloride, Sodium Lactate, Calcium Chloride, Magnesium Chloride	6	1.1	1.1
Ixekizumab	7	1.0	1.0
Abaloparatide	5	0.9	0.9
Galcanezumab-Gnlm	5	0.9	0.9
Dupilumab	70	0.8	0.8
Droxidopa	3	0.8	0.8
Nirmatrelvir And Ritonavir	7	0.7	0.7
Adapalene	3	0.1	0.1

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.